ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 16, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 16, 2012
News
AstraZeneca and Bristol-Myers Squibb Extend Diabetes Alliance
By Stephanie Sutton
AstraZeneca has paid approximately $3.2 billion to extend its diabetes alliance with Bristol-Myers Squibb (BMS), following BMS's recently completed acquisition of Amylin Pharmaceuticals.
Pfizer's Zoetis Subsidiary Files IPO
By Jennifer Markarian
Zoetis, a subsidiary of Pfizer, filed a registration statement with the US Securities and Exchange Commission for a potential initial public offering of Class A common stock.
Elan to Spin Off Discovery Sciences
By Amy Ritter
Elan Corporation announced plans to spin off its discovery unit and Neotope Biosciences division to create an independent entity focused on R&D.
PhRMA Research Awards Focus on Alzheimer's Disease
By Angie Drakulich
On Sept. 12, 2012, PhRMA is cohosting a brand new national awards program in Washington, DC, to honor individuals and organizations that have contributed significantly to the fight against Alzheimer's Disease.
Week of August 13, 2012: Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More
Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here